Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Sells $1,190,564.07 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $1,044.66 on Wednesday. The firm’s fifty day moving average price is $987.40 and its two-hundred day moving average price is $952.81. The stock has a market cap of $115.11 billion, a PE ratio of 30.86, a PEG ratio of 2.17 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $688.52 and a fifty-two week high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on REGN. Royal Bank of Canada restated an “outperform” rating and issued a $1,229.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, June 24th. Morgan Stanley lifted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Cantor Fitzgerald restated a “neutral” rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. Finally, UBS Group upped their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,027.55.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in REGN. Sierra Summit Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $1,011,000. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $749,000. Public Employees Retirement Association of Colorado raised its position in Regeneron Pharmaceuticals by 16.0% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after purchasing an additional 2,220 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after buying an additional 1,221 shares during the period. Finally, Congress Wealth Management LLC DE bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $271,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.